Filing Flows

Filing Flows › 8-K events › SeaStar Medical Holding

SeaStar Medical Holding: other events

Form 8-K filed Nov 3, 2026 · items 8.01

FDA decisionsFDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE ® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

What the filing says

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE ® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients DENVER, CO., November 3, 2026 -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on tra

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

SeaStar Medical Holding at a glance

Latest quarterQ2 2026
Revenue$615K
Revenue Y/Y+82%
Operating margin-616.4%
IndustrySurgical & Medical Instruments & Apparatus

SeaStar Medical Holding, Q2 2026: revenue $615K (+82% year over year), operating margin -616.4%. The chart follows the revenue to costs, profit and cash.

SeaStar Medical Holding: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.